Search clinical trials for: Angiotensin-(1-7)

Total 15884 results

Takeda

Withdrawn

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE)

Essential Hypertension With Stable Angina and Dyslipidemia

Japan
Takeda

Completed

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Pediatric Hypertension

Japan
Boehringer Ingelheim

Terminated

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Hypertension | Coronary Arteriosclerosis

Germany
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Hypertension

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Congestive Heart Failure
Ludwig-Maximilians - University of Munich
Bayer

Completed

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients (METATEL)

Hypertension | Metabolic Syndrome | Hypertriglyceridemia

Germany
Charite University, Berlin, Germany
Bristol-Myers Squibb

Completed

Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure

Chronic Heart Failure

Germany
Novartis

Completed

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

Healthy

United States
Steno Diabetes Center Copenhagen
Bristol-Myers Squibb; Sanofi-Synthelabo

Completed

Irbesartan in Type 2 Diabetes

Hypertension | Type 2 Diabetes | Microalbuminuria
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Irbesartan

Obesity, Morbid

Norway
Takeda

Completed

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Hypertension

Japan
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Boehringer Ingelheim

Completed

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Hypertension
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Hypertension
Boehringer Ingelheim

Completed

Pharmacovigilance and Patient Compliance in Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

BIBR 277 Capsules in Hypertensive Patients With Nephropathy

Hypertension
AstraZeneca

Completed

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Congestive Heart Failure
Sanofi
Bristol-Myers Squibb

Completed

Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria (PRIME)

Hypertension
Saitama Medical University
Non-Profit Organaizaion "LINE"

Unknown

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

Hypertension

Japan
Jikei University School of Medicine

Unknown

A Morbidity-Mortality and Remodeling Study With Valsartan

Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
USDA Grand Forks Human Nutrition Research Center

Completed

Iron Bioavailability From MyPyramid Menus

Nonheme Iron Absorption

United States
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
U.S. Army Medical Research and Development Command

Not yet recruiting

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults (VEE)

Venezuelan Equine Encephalomyelitis

United States
University of Chicago

Completed

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Heart Failure

United States
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Samsung Medical Center

Recruiting

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Breast Cancer | Cardiotoxicity | Prevention | Adjuvant | Trastuzumab

Korea, Republic of
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Cardiorenal Syndrome (CRS)

United States
Takeda

Completed

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Hypertension

Japan
Boehringer Ingelheim

Completed

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Hypertension
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Healthy

India
Boehringer Ingelheim

Completed

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Hypertension
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes
National Taiwan University Hospital
Daiichi Sankyo Taiwan Ltd.

Completed

Evaluation of Effects of Exercise Training and ARB in DM Patients

Exercise Training | Vascular Function

Taiwan
Novartis

Completed

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Hypertension | Type 2 Diabetes | PROTEINURIA
Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Congestive Heart Failure
Gruppo di Ricerca GISSI

Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Atrial Fibrillation

Italy, Switzerland
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
NYU Langone Health

Withdrawn

Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty

Arthrofibrosis

United States
Novartis

Completed

The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure

Hypertension | Congestive Heart Failure
University of Southern Denmark
Bristol-Myers Squibb

Completed

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Myocardial Infarction

Denmark
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials. (DIRECT)

Type 1 Diabetes
ANRS, Emerging Infectious Diseases
Sanofi

Completed

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C (Fibrosar)

Hepatitis C, Chronic

France
Boehringer Ingelheim

Completed

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Hypertension | Diabetic Nephropathies

Spain, Taiwan, Malaysia, Italy, Portugal, France, Czech Republic, Korea, Republic of, Russian Federation, Denmark, Germany, Slovakia, Ukraine
Novartis

Completed

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Hypertension
Slovak Academy of Sciences

Unknown

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

Hypertension

Slovakia
AstraZeneca

Completed

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Hypertension

United States

3

Subscribe